74 cases of diabetes insipidus were reported in this paper. There were polydipsia,polyuris and low specific gravity of urine in all patients. Classification was determinedas follows: pituidary 64 cases (including idiopathic 44 cases, secondary 20 cases),nephritic 8 cases and unclassified 2 cases. Intracranial tumors should be paid altentionto rule out. 12 patients responded very satisfactorily to oral administration of singlechlorpropamide. In order to avoid hypoglycemia, an initjal dose of 10 mg/kg/24hr wasrecommended.

OBJECTIVE:To provide references for the clinical research on the optimized therapeutic regimen in the treatment of cerebral infarction. METHODS:The medication information of 1 738 cases cerebral infarction patients in 8 tertiary grade A hospitals in Shandong province between January 2003 and January 2005 was analyzed statistically. RESULTS:The majority cases were administered with dehydrants,thrombolytic,drugs that could prevent platelet from aggregation,improve cerebral circulation and cerebral metabolism,meanwhile,they were given the combined treatment,chiefly the supporting treatment,the cure rate and improvement rate were 92.69%,the mortality was 3.45%,automatic (without cure)hospital discharge rate was 2.42%,the medication was rational. CONCLUSION:Multi-application,long course of treatment,high prices,heavy economical burden were often the cases in the treatment of cerebral infarction. It is essential to conduct pharmacoeconomics study so as to the lessen patients' economical burden and obtain an optimized therapeutic regime.

Objective:To observe the efficacy and safety of decitabine combined with chemotherapy in treatment of relapsed/refractory T lymphoblastic lymphoma/leukemia (T-LBL/ALL) with TP53 mutation.Methods:The clinical data of a T-LBL/ALL patient with TP53 mutation who had recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) treated with decitabine combined with chemotherapy in the First Affiliated Hospital of Soochow University in June 2018 were retrospectively analyzed and the relevant literature was reviewed.Results:The patient, a 42-year-old male, diagnosed as T-LBL/ALL with TP53 mutation by comprehensive examination underwent sibling-matched donor allo-HSCT after a second complete remission. The patient relapsed 8 months later and was treated with decitabine combined with CLAG regimen to achieve complete remission again. And then, he had leukemia-free survival until now through maintenance treatment with decitabine.Conclusion:Decitabine combined with chemotherapy may be a safe and effective treatment option for relapsed T-LBL/ALL patients with TP53 mutation after allo-HSCT.

Emerging and re-emerging RNA viruses occasionally cause epidemics and pandemics worldwide, such as the on-going outbreak of the novel coronavirus SARS-CoV-2. Herein, we identified two potent inhibitors of human DHODH, S312 and S416, with favorable drug-likeness and pharmacokinetic profiles, which all showed broad-spectrum antiviral effects against various RNA viruses, including influenza A virus, Zika virus, Ebola virus, and particularly against SARS-CoV-2. Notably, S416 is reported to be the most potent inhibitor so far with an EC of 17 nmol/L and an SI value of 10,505.88 in infected cells. Our results are the first to validate that DHODH is an attractive host target through high antiviral efficacy in vivo and low virus replication in DHODH knock-out cells. This work demonstrates that both S312/S416 and old drugs (Leflunomide/Teriflunomide) with dual actions of antiviral and immuno-regulation may have clinical potentials to cure SARS-CoV-2 or other RNA viruses circulating worldwide, no matter such viruses are mutated or not.
Animals ; Antiviral Agents ; pharmacology ; therapeutic use ; Betacoronavirus ; drug effects ; physiology ; Binding Sites ; drug effects ; Cell Line ; Coronavirus Infections ; drug therapy ; virology ; Crotonates ; pharmacology ; Cytokine Release Syndrome ; drug therapy ; Drug Evaluation, Preclinical ; Gene Knockout Techniques ; Humans ; Influenza A virus ; drug effects ; Leflunomide ; pharmacology ; Mice ; Mice, Inbred BALB C ; Orthomyxoviridae Infections ; drug therapy ; Oseltamivir ; therapeutic use ; Oxidoreductases ; antagonists & inhibitors ; metabolism ; Pandemics ; Pneumonia, Viral ; drug therapy ; virology ; Protein Binding ; drug effects ; Pyrimidines ; biosynthesis ; RNA Viruses ; drug effects ; physiology ; Structure-Activity Relationship ; Toluidines ; pharmacology ; Ubiquinone ; metabolism ; Virus Replication ; drug effects